Merck and Moderna announced Wednesday that their personalized mRNA cancer vaccine significantly reduced melanoma recurrence when added to Merck's immunotherapy drug Keytruda. The trial is a Phase 3 study—the largest and most rigorous stage of clinical testing—and the first randomized late-stage trial to establish whether neoantigen vaccines work against cancer.
The vaccine, called intismeran, targets neoantigens—protein fragments that appear on cancer cell surfaces as a result of tumor-specific mutations. Because every patient's tumor carries a different set of mutations, the vaccine is manufactured individually for each patient.
The trial tested intismeran in adjuvant melanoma, meaning patients whose disease had already been surgically removed. The goal was to prevent recurrence or metastatic spread. The combination of intismeran and Keytruda met the primary endpoint, reducing both recurrence and metastatic spread compared with Keytruda alone.
Melanoma is the deadliest form of skin cancer. Keytruda—generic name pembrolizumab—is already a standard treatment in this setting, making the trial a genuine test of added benefit rather than a comparison against a weaker control.
Neoantigen vaccines have attracted scientific interest for more than a decade on the theory that training a patient's immune system to recognize tumor-specific mutations would produce a targeted attack on cancer cells. Earlier-phase data from intismeran had been encouraging, but Phase 3 randomized trials are the standard regulators and the medical community require before a treatment becomes part of routine care.
Moderna's shares rose 60 percent in premarket trading following the news. The companies said they did not immediately release detailed trial data, meaning full efficacy and safety numbers have not yet been published or presented at a medical conference.
The mRNA platform underlying intismeran is the same technology Moderna used for its COVID-19 vaccine. In the cancer application, the mRNA instructs the patient's immune cells to recognize and attack the specific mutations found in that individual's tumor. The manufacturing process requires sequencing the patient's tumor, identifying relevant mutations, designing the mRNA sequence and producing a custom dose—a pipeline that previously took months but has been compressed as the technology matured.
For Moderna, a positive Phase 3 result carries commercial weight beyond melanoma. The company has built its post-COVID pipeline around mRNA therapeutics, and intismeran is the lead asset in that program. A regulatory submission to the Food and Drug Administration would be the next step, though the timeline depends on when the companies release full trial data and whether the FDA grants accelerated review designation.
For Merck, the result extends Keytruda's utility in a setting where it already dominates. Keytruda generated $29.5 billion in global sales in 2024, making it the best-selling drug in the world. Adding an approved combination partner in adjuvant melanoma would deepen the drug's position in a market it leads and potentially establish a template for combining Keytruda with personalized vaccines in other tumor types.
The open question is durability of benefit. The companies have not released progression-free survival curves or overall survival data—the metrics oncologists use to judge whether a treatment genuinely extends life rather than delaying recurrence by a short margin. Full data presentation at a major oncology conference, likely ASCO or ESMO, will determine how the medical community receives the results and how aggressively regulators move.
A manufacturing challenge will define intismeran's commercial reach. A personalized vaccine requires a separate production run for every patient. Scaling that process while keeping turnaround times short enough to be clinically practical—ideally before residual disease can re-establish itself after surgery—is an operational challenge that no company has solved at commercial volume. Moderna has not disclosed current turnaround times or production capacity targets for intismeran.
If full data confirm the Phase 3 readout, the result places mRNA squarely in the cancer treatment toolkit alongside surgery, checkpoint immunotherapy and chemotherapy—not as a replacement for existing treatments but as an add-on that demonstrably improves outcomes in at least one tumor type. Whether the same approach works in lung cancer, colorectal cancer or other solid tumors where Merck and Moderna are running trials remains an open empirical question.
